Table 1.
Differential expressed proteins (empagliflozin vs. placebo) at Week 12
| Protein | UniprotID | Before adjustment for change in eGFR | After adjustment for change in eGFR | ||
|---|---|---|---|---|---|
| Empagliflozin vs. placebo, log2 fold change (95% CI) | False discovery rate (%) | Empagliflozin vs. placebo, log2 fold change (95% CI) | False discovery rate (%) | ||
| IGFBP1 | P08833 | 0.27 (0.14–0.40) | 0.16 | 0.25 (0.13–0.38) | 0.55 |
| TfR1 | P02786 | 0.26 (0.19–0.32) | <0.0001 | 0.25 (0.18–0.32) | <0.001 |
| CA2 | P00918 | 0.25 (0.11–0.39) | 0.81 | 0.26 (0.12–0.40) | 1.02 |
| EPO | P01588 | 0.25 (0.11–0.38) | 0.65 | 0.24 (0.10–0.37) | 1.53 |
| TGM2 | P21980 | 0.25 (0.11–0.38) | 0.60 | 0.25 (0.12–0.38) | 1.02 |
| TMSB10 | P63313 | 0.22 (0.11–0.34) | 0.43 | 0.19 (0.08–0.31) | 2.18 |
| uMtCK | P12532 | 0.21 (0.10–0.32) | 0.43 | 0.22 (0.11–0.33) | 0.69 |
| IGFBP4 | P22692 | 0.21 (0.13–0.30) | 0.01 | 0.17 (0.09–0.25) | 0.31 |
| AFABP4 | P15090 | 0.21 (0.12–0.29) | 0.02 | 0.17 (0.09–0.25) | 0.31 |
| CCL18 | P55774 | 0.20 (0.11–0.29) | 0.08 | 0.19 (0.10–0.28) | 0.31 |
| Follistatin | P19883 | 0.20 (0.13–0.26) | <0.0001 | 0.19 (0.12–0.26) | <0.0001 |
| Midkine | P21741 | 0.20 (0.11–0.29) | 0.14 | 0.18 (0.09–0.27) | 0.55 |
| Guanylin | Q02747 | 0.20 (0.13–0.26) | <0.0001 | 0.17 (0.11–0.23) | <0.001 |
| SPINK1 | P00995 | 0.20 (0.13–0.26) | <0.01 | 0.16 (0.10–0.23) | 0.02 |
| Rarres2 | Q99969 | 0.19 (0.10–0.29) | 0.18 | 0.17 (0.08–0.27) | 0.96 |
| CNDP1 | Q96KN2 | 0.19 (0.11–0.28) | 0.07 | 0.19 (0.11–0.27) | 0.19 |
| EpCAM | P16422 | 0.19 (0.10–0.28) | 0.17 | 0.20 (0.10–0.29) | 0.29 |
| CCL27 | Q9Y4X3 | 0.19 (0.09–0.29) | 0.61 | 0.17 (0.07–0.27) | 2.16 |
| SRCR | Q8WTU2 | 0.18 (0.09–0.27) | 0.21 | 0.18 (0.09–0.27) | 0.48 |
| PLA2 | P14555 | 0.18 (0.08–0.27) | 0.54 | 0.16 (0.07–0.26) | 2.07 |
| Promotilin | P12872 | 0.18 (0.09–0.26) | 0.26 | 0.16 (0.08–0.25) | 1.02 |
| ANGPTL4 | Q9BY76 | 0.17 (0.11–0.23) | 0.00 | 0.16 (0.09–0.22) | 0.01 |
| RBP2 | P50120 | 0.17 (0.07–0.26) | 0.98 | 0.15 (0.05–0.24) | 4.02 |
| Uromodulin | P07911 | 0.16 (0.10–0.22) | <0.0001 | 0.18 (0.12–0.23) | <0.0001 |
| Cystatin-F | O76096 | 0.16 (0.07–0.25) | 0.63 | 0.15 (0.06–0.24) | 1.89 |
| CCN5 | O76076 | 0.15 (0.08–0.22) | 0.14 | 0.14 (0.07–0.21) | 0.69 |
| CCL16 | O15467 | 0.15 (0.08–0.22) | 0.19 | 0.13 (0.06–0.21) | 1.02 |
| Osteopontin | P10451 | 0.14 (0.08–0.21) | 0.18 | 0.13 (0.06–0.20) | 1.02 |
| ANGPTL2 | Q9UKU9 | 0.14 (0.07–0.22) | 0.54 | 0.14 (0.06–0.21) | 1.16 |
| NPDC1 | Q9NQX5 | 0.14 (0.08–0.21) | 0.07 | 0.11 (0.06–0.17) | 1.02 |
| Elafin | P19957 | 0.14 (0.07–0.21) | 0.44 | 0.11 (0.04–0.18) | 3.96 |
| Cystatin-M | Q15828 | 0.14 (0.08–0.20) | 0.10 | 0.11 (0.05–0.17) | 1.02 |
IGFBP1, insulin-like growth factor-binding protein 1; TfR1, transferrin receptor protein 1; CA2, carbonic anhydrase 2; EPO, erythropoietin; TGM2, protein-glutamine gamma-glutamyltransferase 2; TMSB10, thymosin beta-10; uMtCK, creatine kinase U-type, mitochondrial; IGFBP4, insulin-like growth factor-binding protein 4; AFABP, adipocyte fatty acid-binding protein 4; CCL18, C–C motif chemokine 18; SPINK1, serine protease inhibitor Kazal-type 1; Rarres2, retinoic acid receptor responder protein 2; CNDP1, beta-Ala-His dipeptidase; EpCAM, epithelial cell adhesion molecule; CCL27, C–C motif chemokine 27; SRCR, scavenger receptor cysteine-rich domain-containing group B protein; PLA2, phospholipase A2; ANGPTL4, angiopoietin-related protein 4; RBP2, retinol-binding protein 2; CCN5, CCN family member 5; CCL16, C–C motif chemokine 16; NPDC1, neural proliferation differentiation and control protein 1; ANGPTL2, angiopoietin-related protein 2.